Skip to main content Back to Top
Advertisement

3/8/2021

Azacitidine Injection

Products Affected - Description

    • Vidaza lyophilized powder for injection, Bristol-Myers Squibb, 100 mg, vial, 1 count, NDC 59572-0102-01
    • Azacitidine lyophilized powder for injection, Accord, 100 mg, vial, 1 count, NDC 16729-0306-10
    • Azacitidine lyophilized powder for injection, Armas Pharmaceuticals, 100 mg, vial, 1 count, NDC 72485-0201-01
    • Azacitidine lyophilized powder for injection, Cipla USA, 100 mg, vial, 1 count, NDC 69097-0805-40
    • Azacitidine lyophilized powder for injection, Dr. Reddy's, 100 mg, vial, 1 count, NDC 43598-0305-62
    • Azacitidine lyophilized powder for injection, Fresenius Kabi, 100 mg, vial, 1 count, NDC 63323-0771-39
    • Azacitidine lyophilized powder for injection, Hikma, 100 mg, vial, 1 count, NDC 00143-9606-01
    • Azacitidine lyophilized powder for injection, Mylan Institutional, 100 mg, vial, 1 count, NDC 67457-0254-30
    • Azacitidine lyophilized powder for injection, Wockhardt USA, 100 mg, vial, 1 count, NDC 64679-0096-01

Reason for the Shortage

    • Accord has azacitidine on back order due to a shortage of the raw ingredient.
    • Armas has azacitidine on shortage due to increased demand.
    • Dr. Reddy's has azacitidine on shortage due to increased demand.
    • Fresenius Kabi has azacitidine on shortage due to increased demand.
    • Hikma has azacitidine on shortage due to increased demand.
    • Mylan Institutional did not provide a reason for the shortage.
    • Sandoz has azacitidine on shortage due to increased demand.
    • Wockhardt did not provide a reason for the shortage.
    • Celgene (now part of Bristol-Myers Squibb) has Vidaza on shortage due to increased demand.

Available Products

    • Azacitidine lyophilized powder for injection, Sandoz, 100 mg, vial, 1 count, NDC 00781-3253-94

Estimated Resupply Dates

    • Accord has azacitidine 100 mg vials on back order and the company cannot estimate a release date.
    • Armas has azacitidine 100 mg vials on back order and the company cannot estimate a release date.
    • Celgene has Vidaza 100 mg vials on allocation.
    • Cipla has azacitidine 100 mg vials on back order and the company cannot estimate a release date.
    • Dr. Reddy's has azacitidine 100 mg vials on intermittent back order and the company is releasing product as it becomes available.
    • Fresenius Kabi has azacitidine 100 mg vials on back order and the company cannot estimate a release date.
    • Hikma has azacitidine 100 mg vials on allocation.
    • Mylan Institutional has azacitidine 100 mg vials on back order and the company estimates a release date of late-March to early-April 2021.
    • Wockhardt has azacitidine 100 mg vials on back order and the company cannot estimate a release date.

Updated

Updated March 8, 2021 by Michelle Wheeler, PharmD, Drug Information Specialist. Created November 2, 2020 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2021, Drug Information Service, University of Utah, Salt Lake City, UT.

ADVERTISEMENT

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.